You are here

Researchers adapt CAR-T immunotherapy to target the HIV latent reservoir

Friday, October 25, 2019

A team of Gladstone scientists and their partners at Xyphos Biosciences, Inc. describe a new way of attacking cells infected by HIV in this week's issue of the journal Cell. The work showcases a novel version of CAR-T, the technology known for its recent successes in fighting blood cancers. With improvements lending it greater breadth of coverage and versatility, the new technology, called convertibleCAR, shows great promise in several therapeutic areas, particularly in the fight against HIV, as it could be used to shrink the reservoir of infected cells that persists in patients under antiretroviral therapy.

Click here for more!